Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Ernexa Therapeutics (Nasdaq: ERNA) will present in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026 at 4:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ernexa Therapeutics (Nasdaq: ERNA) will present in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026 at 4:00 PM ET. CEO Sanjeev Luther will give a corporate overview and business outlook, take live questions, and a replay will be available two hours after the live event for 90 days.
Investors may register to attend the live webcast and submit questions during the moderated discussion.
Details
News Market Reaction – ERNA
On Feb 20, the day this news came out, ERNA closed 17.25% below the previous close.
Data tracked by StockTitan Argus for the Feb 20 session.
Key Figures
- Event date
- February 25, 2026
- Virtual Investor Closing Bell Series participation
- Start time
- 4:00 PM ET
- Scheduled time of live webcast
- Replay availability
- 90 days
- Duration webcast replay will remain accessible
Historical Context
-
Best-efforts $10.5M equity and warrant offering priced at $0.50 per unit.
-
Virtual Investor segment discussing successful Pre-IND meeting and ERNA-101 plans.
-
Selected among 10 companies for JETRO JEAP to support Japan market entry.
-
Successful FDA Pre-IND meeting outlining path to first-in-human ERNA-101 trial.
-
ASH preclinical data showing strong immune modulation and survival benefits for ERNA-101.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET
Register here
CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that Sanjeev Luther, President & CEO of Ernexa, will participate in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026, at 4:00 PM ET.
As part of the segment, Sanjeev Luther, President & CEO of Ernexa, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.ernexatx.com.
Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com
Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.